United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

25 Jul 2016
Change (% chg)

$2.00 (+2.31%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Mon, Jul 25 2016

Gilead cuts 2016 sales forecast, cites hepatitis C drugs

Gilead Sciences Inc on Monday lowered its full-year sales outlook, citing slower-than-expected demand for its key hepatitis C drugs, and said second-quarter profits fell 22 percent.

Gilead second-quarter net profit falls 22 percent

July 25 Gilead Sciences Inc said on Monday its second-quarter net profit fell 22 percent, due mostly to lower sales of its hepatitis C drug Harvoni.

BRIEF-Gilead Sciences sets qtrly dividend of $0.47 per share

* Sets quarterly cash dividend of $0.47per share Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Gilead Sciences Q2 non-GAAP earnings per share $3.08

* Q2 Harvoni sales $ 2.56 billion versus $3.61 billion last year

BRIEF-EMA adopts positive opinion on expanded approval of Gilead's HIV drug, Truvada

* European CHMP adopts positive opinion on Gilead's type II variation application for Truvada for reducing the risk of sexually acquired HIV.

BRIEF-Gilead's Odefsey meets primary objective in phase 3B studies

* Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week objective in two phase 3B studies

BRIEF-Gilead Sciences gets Canada approval for Hepatitis C treatment Epclusa

* Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic Hepatitis C Source text for Eikon: Further company coverage:

BRIEF-Ligand enters into Omniab platform license agreement with Gilead Sciences

* Ligand enters into Omniab platform license agreement with Gilead Sciences

AIDS Healthcare Foundation lawsuit over Gilead AIDS drugs dismissed

A California federal judge has dismissed a lawsuit filed by the non-profit AIDS Healthcare Foundation challenging Gilead Sciences' patents on AIDS drugs and accusing it of suppressing competition.

Merck appeals order reversing its $200 mln verdict against Gilead

Merck & Co has appealed a California federal judge's order that overturned a $200 million verdict it won in a patent case against Gilead Sciences over Gilead's lucrative hepatitis C drugs on the grounds that Merck engaged in extensive misconduct.

Select another date: